OR WAIT 15 SECS
CenExel Clinical Research, Inc., announced the creation of their Centers of Excellence company, which unites clinical research units to design and execute Phase I-IV trials, including Phase I studies in patient populations, to help pharmaceutical companies improve the time and cost of new therapy development for better patient care.
CenExel operates in Utah, California, Georgia and Maryland.
The CenExel Centers of Excellence include JBR Clinical Research, Atlanta Center for Medical Research (ACMR), Anaheim Clinical Trials (ACT), and CBH Health, research facilities in respective fields: post-operative pain, central nervous system (CNS) disorders, chronic disease management, Asian pharmacokinetic bridging studies, psychiatric illnesses, and others.
"CenExel Centers of Excellence offer pharmaceutical companies and clinical research organizations access to some of the finest investigators and facilities in the world for conducting research," said Tom Wardle, CEO. "We are focused on delivering the highest possible quality through our combined expertise, the engagement of our investigators and staff, and most importantly, our results."
Their principal investigators include Todd Bertoch, MD, Robert A. Reisenberg, MD, Peter Winkle, MD, and Robert E. Litman, MD. Dr. Bertoch also chairs the CenExel Scientific Advisory Board with noted analgesia research experts Stephen Cooper, DMD, PhD, and Paul Desjardins, DMD, PhD.
Kevin Quinn, VP of Business Development and Integration, said, "The level of engagement among staff and patients is a key differentiator with our Centers of Excellence. This commitment has enabled our Centers to routinely meet or exceed patient recruitment goals in hundreds of clinical trials, so we are able to complete studies on-time and within budget."